Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of October 2023, specifically dated October 2, 2023. The report serves to disseminate a press release regarding clinical validation of the Company's ProSense Cryoablation technology for breast cancer treatment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change disclosed is the publication of an independent study validating the safety and efficacy of the Company's ProSense Cryoablation procedure. The study reports a 96.8% success rate for the outpatient procedure in treating breast cancer.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the accompanying press release (Exhibit 99.1). The text does not provide specific numerical guidance, detailed management commentary on future operations, or a list of specific risks beyond the standard incorporation of forward-looking statements into the Company's registration forms.
Investor Verification Checklist
- Verify the full text of the independent study referenced in Exhibit 99.1 to understand the methodology and sample size behind the 96.8% success rate.
- Review the "Forward Looking Statements" section in the press release for specific caveats regarding future commercialization or regulatory approval.
- Confirm the status of the Company's Registration Statements on Form F-3 and Form S-8 where this information is incorporated.